PT  - JOURNAL ARTICLE
AU  - Parikh, Nehal A.
AU  - Sharma, Puneet
AU  - He, Lili
AU  - Li, Hailong
AU  - Altaye, Mekibib
AU  - Priyanka Illapani, Venkata Sita
AU  - ,
TI  - Perinatal Risk and Protective Factors in the Development of Diffuse White Matter Abnormality on Term-Equivalent Age MRI in Infants Born Very Preterm
AID  - 10.1101/2020.08.01.20166488
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.01.20166488
4099  - http://medrxiv.org/content/early/2020/08/04/2020.08.01.20166488.short
4100  - http://medrxiv.org/content/early/2020/08/04/2020.08.01.20166488.full
AB  - Importance Diffuse white matter abnormality (DWMA) is the most common brain MRI finding in very preterm infants and is predictive of neurodevelopmental impairments. However, its etiology remains elusive and identifying perinatal risk and protective factors may allow clinicians to reduce the burden of DWMA.Objective To identify perinatal clinical factors that are associated with the development of objectively diagnosed DWMA in very preterm infants.Design A prospective cohort was enrolled between September 2016 and November 2019. Brain MRIs were collected at 39 to 45 weeks postmenstrual age (PMA) to evaluate DWMA volume. A pre-defined list of pertinent maternal characteristics, pregnancy/delivery data, and neonatal ICU data was collected for enrolled patients to identify antecedents of objectively diagnosed DWMA.Setting Five level III/IV NICUs in the greater Cincinnati, Ohio area.Participants A population-based sample of 392 very preterm infants born before 33 weeks gestational age.Exposure Very preterm birth with associated diseases and treatments.Main Outcome and Measure Objectively diagnosed DWMA volume on brain MRI at term-equivalent age.Results 377 of the 392 very preterm infants (96%) had high quality MRI data. Mean (SD) gestational age was 29.3 (2.5) weeks. In multivariable linear regression analyses, pneumothorax (p=.027), severe bronchopulmonary dysplasia (BPD) (p=.009), severe retinopathy of prematurity (ROP) (p<0.001), and male sex (p=.041) were associated with increasing volume of DWMA. The following factors were associated with decreased risk of DWMA – dexamethasone for severe BPD (p=.004), duration of caffeine for severe BPD (p = 0.009), and exclusive maternal milk at NICU discharge (p=.049).Conclusions and Relevance Severe ROP and BPD exhibited the strongest adverse association with the development of DWMA. Caffeine and dexamethasone treatments for infants with severe BPD exhibited a protective effect against development of DWMA. The beneficial association with maternal milk is also a modifiable factor that has clinical implications.Question What perinatal clinical factors are independently associated with the development of diffuse white matter abnormality (DWMA) in very preterm infants?Findings In this prospective cohort study, pneumothorax, severe bronchopulmonary dysplasia (BPD), severe retinopathy of prematurity, and male sex were significantly associated with an increased risk of DWMA. Significant protective factors included dexamethasone for severe BPD, duration of caffeine for severe BPD, and exclusive maternal milk diet at NICU discharge.Meaning Knowledge of these common and modifiable neonatal diseases and treatments may allow clinicians to reduce the burden of DWMA development through targeted prevention or treatments approaches.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by National Institutes of Health grants R01-NS094200-05 and R01-NS096037-03 from the National Institute of Neurological Disorders and Stroke (NINDS).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Cincinnati Childrens Hospital Institutional Review Board approved the study, and the review boards of the other hospitals approved the study based on an established reliance agreement.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.